Clinical Trials Directory

We are doing this study to collect cerebrospinal fluid (CSF) samples from people with cancer that has spread to the leptomeninges (the inner membranes that cover the brain and spinal cord). These CSF samples will be used in laboratory research projects to identify substances called biomarkers. Biomarker testing is a way to look for genes, proteins, and other substances (tumor markers) that can provide information about cancer. Information from these CSF samples may help us learn about new methods to treat metastatic disease to the leptomeninges.

We are doing this study to find out if an investigational drug called tocilizumab (the study drug) will lead to better outcomes after lung transplantation when it is combined with standard anti-rejection medicines.

We are doing this research to learn more about whether taking a blood thinner, along with medications that prevent blood clots, improve outcomes in patients who develop atrial fibrillation (irregular heartbeat) after coronary artery bypass grafting surgery.

We are doing this study to compare treatment options for mitral valve regurgitation.

We are doing this study to find out if an investigational drug called CA-4948 is a safe and effective option for people with PCNSL. We want to know how well it works when it is combined with a drug called ibrutinib, which is commonly used to treat PCNSL.

We are doing this study to find out if an experimental drug called CT01681 (the study drug) is a safe and effective option for people who get CAR T-cell therapy as a treatment for diffuse large B cell lymphoma (DLBCL). We want to know if the study drug has the potential to lower or prevent certain side effects of CAR T-cell therapy. The possible side effects of CAR T-cell therapy that the study drug is being developed to protect against are called cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This study is enrolling people who will receive an available form of CAR T-cell therapy called YESCARTA.